Remove Medicine Remove Networking Remove Pharmaceutical products Remove Prescription
article thumbnail

KFA-115 by Novartis for Melanoma: Likelihood of Approval

Pharmaceutical Technology

Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. The company offers generic medicines and biosimilars through Sandoz.

article thumbnail

KFA-115 by Novartis for Malignant Mesothelioma: Likelihood of Approval

Pharmaceutical Technology

Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. The company offers generic medicines and biosimilars through Sandoz.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Iptacopan hydrochloride by Novartis for Paroxysmal Nocturnal Hemoglobinuria: Likelihood of Approval

Pharmaceutical Technology

Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. The company offers generic medicines and biosimilars through Sandoz.

article thumbnail

Iptacopan hydrochloride by Novartis for Glomerulonephritis: Likelihood of Approval

Pharmaceutical Technology

Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. The company offers generic medicines and biosimilars through Sandoz.

article thumbnail

New IFPMA and EFPIA guidance on use of social media by the pharmaceutical industry

pharmaphorum

Digital channels are defined as “ platforms for electronic communication through transmission of digital content over the internet or computer networks. The Guidance applies to both product-related and therapeutic-area-related activities. Why is guidance needed? Digital Channels include, but are not limited to, social media ”.

Media 87
article thumbnail

Pharma within planetary boundaries

European Pharmaceutical Review

Giving environmental risk assessments teeth Since 2005, the authorisation of a human pharmaceutical product requires an environmental risk assessment (ERA). Interestingly, this is not the case for veterinary medicines, where the authorisation can actually be refused if the risk is not adequately mitigated.

Pharma 80
article thumbnail

Edoxaban tosylate by Daiichi Sankyo for Atrial Fibrillation: Likelihood of Approval

Pharmaceutical Technology

Daiichi Sankyo overview Daiichi Sankyo is a holding company, which carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, over the counter (OTC) drugs, vaccines, and others. Daiichi Sankyo is headquartered in Tokyo, Japan.